December 9, 2021
To Register: https://us06web.zoom.us/webinar/register/WN_p2JRbQn4RFOYjwMhJih9bQ?mkt_tok=NDkwLUVIWi05OTkAAAGAi-v-8gZGj5dS2mmdNTebYRFtkBI1hHrps3DPU5xEQmBKnDx4ZxbkN4QAGpDco73It6wrgKvv6IfkcVnnmOIW0HM3a9vg31uWgq_qR3mLHRER
A private biotech that announces a definitive agreement with a SPAC jumps into the public investor spotlight and faces that attention with fewer guardrails than the IPO process, plus a need to transform board, investor, and regulatory relations. Given that most SPAC merger deals also involve follow-on PIPE investment rounds or other transactions, the full fundraising benefits of the deal strategy require a smooth de-SPAC process that a private biotech would never have encountered before. Join this webinar to learn best practices for navigating from SPAC deal announcement through de-SPAC process to regular life managing a publicly traded company. Interact with the following dealmaking experts to ask them your own questions during the session.
— Barbara Ryan, Founder, Barbara Ryan Advisors; Editorial Advisory Board, Pharmaceutical Executive; Senior Advisor, EY
— Julia Forbess, Partner, Fenwick & West LLP
— Jonas Grossman, President and Managing Partner, Chardan
— Jeet Mahal, Chief Financial and Business Officer, Jasper Therapeutics
— Anna Mowry, Chief Financial Officer, Nautilus Bio
This session is part of the "Anatomy of a SPAC Deal" Webinar Series,
sponsored by Chardan.